Critical Comparison: Cullinan Oncology (NASDAQ:CGEM) versus Immunocore (NASDAQ:IMCR)

Cullinan Oncology (NASDAQ:CGEM) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Profitability

This table compares Cullinan Oncology and Immunocore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cullinan Oncology N/A -19.17% -15.42%
Immunocore N/A N/A N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cullinan Oncology and Immunocore, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Oncology 0 0 4 0 3.00
Immunocore 0 1 3 0 2.75

Cullinan Oncology currently has a consensus target price of $51.75, suggesting a potential upside of 278.01%. Immunocore has a consensus target price of $54.75, suggesting a potential upside of 138.56%. Given Cullinan Oncology’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Cullinan Oncology is more favorable than Immunocore.

Valuation and Earnings

This table compares Cullinan Oncology and Immunocore’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cullinan Oncology N/A N/A -$51.80 million N/A N/A
Immunocore $38.67 million 25.60 -$95.14 million N/A N/A

Cullinan Oncology has higher earnings, but lower revenue than Immunocore.

Insider and Institutional Ownership

87.7% of Cullinan Oncology shares are owned by institutional investors. Comparatively, 44.1% of Immunocore shares are owned by institutional investors. 21.8% of Cullinan Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cullinan Oncology beats Immunocore on 6 of the 9 factors compared between the two stocks.

Cullinan Oncology Company Profile

Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Immunocore Company Profile

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.